Open AccessHigher dose weekly fluoxetine in hemodialysis patients: A case series report
Author(s) -
Kelley Kauffman,
Jacqueline Dolata,
Maria Figueroa,
Douglas D. Gunzler,
Anne M. Huml,
Julie Pencak,
Ashwini R. Sehgal,
Martha Sajatovic
Publication year - 2020
Publication title -
international journal of psychiatry in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.458
H-Index - 55
eISSN - 1541-3527
pISSN - 0091-2174
DOI - 10.1177/0091217420913399
Subject(s) - fluoxetine , hemodialysis , medicine , antidepressant , major depressive disorder , dose , population , depression (economics) , psychiatry , mood , serotonin , anxiety , receptor , environmental health , economics , macroeconomics
The antidepressant medication fluoxetine at 90 mg dosed weekly is as effective and safe as standard formulation fluoxetine 20 mg dosed daily in patients with major depressive disorder. Weekly fluoxetine has not been well studied in hemodialysis patients, and doses beyond 90 mg/week have not been described in this population. This case series, derived from a larger study on depression in hemodialysis patients, describes the use of weekly fluoxetine at dosages beyond 90 mg/week.